Qianjiang Yongan Pharmaceutical Co., Ltd. (002365) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Qianjiang Yongan Pharmaceutical Co., Ltd.

Why is Qianjiang Yongan Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 5.32%

The company has been able to generate a Return on Capital Employed (avg) of 5.32% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -8.67% and Operating profit at -171.19% over the last 5 years

Negative results in Sep 25

INTEREST(HY) At CNY 0.51 MM has Grown at 73.83%
OPERATING CASH FLOW(Y) Lowest at CNY 142.95 MM
NET PROFIT(HY) At CNY 27.75 MM has Grown at -22.58%

With ROE of 0.94%, it has a expensive valuation with a 2.59 Price to Book Value

Over the past year, while the stock has generated a return of 51.06%, its profits have risen by 161.4% ; the PEG ratio of the company is 1.7
At the current price, the company has a high dividend yield of 0.6

Market Beating Performance

The stock has generated a return of 51.06% in the last 1 year, much higher than market (China Shanghai Composite) returns of 13.33%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Qianjiang Yongan Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Specialty Chemicals should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Specialty Chemicals)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Qianjiang Yongan Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Qianjiang Yongan Pharmaceutical Co., Ltd.

57.57%

1.17

64.89%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-8.67%

EBIT Growth (5y)

-171.19%

EBIT to Interest (avg)

14.14

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.44

Sales to Capital Employed (avg)

0.44

Tax Ratio

18.84%

Dividend Payout Ratio

47.46%

Pledged Shares

Institutional Holding

ROCE (avg)

5.32%

ROE (avg)

4.31%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

274

Industry P/E

Price to Book Value

2.59

EV to EBIT

-178.05

EV to EBITDA

45.86

EV to Capital Employed

3.89

EV to Sales

5.43

PEG Ratio

1.70

Dividend Yield

0.58%

ROCE (Latest)

-2.19%

ROE (Latest)

0.94%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

PRE-TAX PROFIT(Q)

At CNY 9.05 MM has Grown at 157.03%

RAW MATERIAL COST(Y)

Fallen by -21.81% (YoY

CASH AND EQV(HY)

Highest at CNY 1,853.16 MM

DEBT-EQUITY RATIO (HY)

Lowest at -45.22 %

NET PROFIT(Q)

Highest at CNY 14.72 MM

-19What is not working for the Company

INTEREST(HY)

At CNY 0.51 MM has Grown at 73.83%

OPERATING CASH FLOW(Y)

Lowest at CNY 142.95 MM

NET PROFIT(HY)

At CNY 27.75 MM has Grown at -22.58%

OPERATING PROFIT(Q)

Lowest at CNY -3.85 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -1.84 %

Here's what is working for Qianjiang Yongan Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 9.05 MM has Grown at 157.03%

over average net sales of the previous four periods of CNY 3.52 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 14.72 MM has Grown at 154.21%

over average net sales of the previous four periods of CNY 5.79 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Profit

Highest at CNY 14.72 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Cash and Eqv

Highest at CNY 1,853.16 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -45.22 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -21.81% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Qianjiang Yongan Pharmaceutical Co., Ltd.

Interest

At CNY 0.51 MM has Grown at 73.83%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Cash Flow

Lowest at CNY 142.95 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Operating Profit

Lowest at CNY -3.85 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -1.84 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales